Evidence map›Paper›PMID 41496203›Full record

ArticleRedox biology2026

Synergistic STING activation and oxidative cascades-induced ferroptosis drive tumor microenvironment remodeling by engineered manganese nanoreactors.

Wa Li, Zihui Tang, Jiyang Xue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Editorial: Research on nanomaterials in tumor diagnosis and therapy, volume II.Frontiers in bioengineering and biotechnology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wa LiDepartment of Medical Affairs, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 200092, PR China; Department of Stomatology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, PR China.
Zihui TangDepartment of Medical Oncology, Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201620, PR China.
Jiyang XueDepartment of Medical Affairs, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 200092, PR China; Department of Pharmacy, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 200092, PR China. Electronic address: xuejiyang7635@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In head and neck squamous cell carcinoma, a "cold" (immune-desert) tumor microenvironment promotes immunosuppression, which is a critical driver of disease recurrence and therapeutic resistance. To address this challenge, we develop an innovative strategy to remodel the tumor immune microenvironment by disrupting intracellular redox balance to induce ferroptosis and immunogenic cell death, synergistically activating STING pathway to facilitating the transition of tumors from a "cold" to a "hot" immunophenotype. In this study, hyaluronic acid-functionalized hollow manganese dioxide nanoparticles loading β-lapachone (hMnL), engineered for targeted chemo-immunotherapy is constructed. In vitro investigations reveal that hMnL induces robust reactive oxygen species (ROS) generation, triggering ferroptosis and immunogenic cell death. Concurrently, Mn

Indexed as

FerroptosisManganeseManganese CompoundsMembrane ProteinsNanoparticlesOxidesTumor MicroenvironmentAnimalsCell Line, TumorcGAS-STING Signaling PathwayDendritic CellsHumansMiceOxidation-ReductionReactive Oxygen SpeciesSTING ProteinManganeseManganese Compoundsmanganese dioxideMembrane ProteinsOxidesReactive Oxygen SpeciesSTING1 protein, humanSTING ProteinChemodynamical therapyFerroptosisImmunogenic cell deathManganese nanoreactorsSTING pathway

Identifiers

PMID41496203
PMCPMC12808843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.